Celldex Therapeutics Net Income Over Time
| CLDX Stock | USD 23.00 0.57 2.42% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Celldex Therapeutics Performance and Celldex Therapeutics Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Celldex Therapeutics. Projected growth potential of Celldex fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Celldex Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (3.30) | Revenue Per Share | Quarterly Revenue Growth (0.71) | Return On Assets | Return On Equity |
Understanding Celldex Therapeutics requires distinguishing between market price and book value, where the latter reflects Celldex's accounting equity. The concept of intrinsic value - what Celldex Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Celldex Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Celldex Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Celldex Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Celldex Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Celldex Therapeutics and related stocks such as Vera Therapeutics, Abcellera Biologics, and Janux Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VERA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (53.4 M) | (32.6 M) | (89.1 M) | (96 M) | (152.1 M) | (136.9 M) | (130.1 M) |
| ABCL | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | (2.2 M) | 118.9 M | (2.2 M) | 158.5 M | (146.4 M) | (162.9 M) | (146.6 M) | (139.2 M) |
| JANX | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (6.8 M) | (32.6 M) | (54.2 M) | (58.3 M) | (69 M) | (62.1 M) | (59 M) |
| IMNM | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (10.6 M) | (17.1 M) | (24.7 M) | (36.9 M) | (106.8 M) | (293 M) | (263.7 M) | (250.5 M) |
| BHVN | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (118.7 M) | (213.8 M) | (570.3 M) | (408.2 M) | (846.4 M) | (761.8 M) | (723.7 M) |
| SYRE | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (11.3 M) | (21.7 M) | (27.2 M) | (44.3 M) | (78.3 M) | (80.9 M) | (65.8 M) | (83.8 M) | (338.8 M) | (208 M) | (187.2 M) | (177.9 M) |
| QURE | (22.4 M) | (22.4 M) | (19.5 M) | (37 M) | (45 M) | (78.1 M) | (73.4 M) | (80.4 M) | (83.3 M) | (124.2 M) | (125 M) | 329.6 M | (126.8 M) | (308.5 M) | (239.6 M) | (215.6 M) | (204.8 M) |
| SION | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (40.2 M) | (47.3 M) | (61.7 M) | (55.5 M) | (58.3 M) |
| HRMY | (39.9 M) | (39.9 M) | (39.9 M) | (39.9 M) | (39.9 M) | (39.9 M) | (39.9 M) | (39.9 M) | (39.9 M) | (152 M) | (36.9 M) | 34.6 M | 181.5 M | 128.9 M | 145.5 M | 167.3 M | 175.7 M |
| NUVB | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (992 K) | (33.6 M) | (41.7 M) | (86.8 M) | (104.2 M) | (75.8 M) | (567.9 M) | (511.1 M) | (485.6 M) |
Celldex Therapeutics and related stocks such as Vera Therapeutics, Abcellera Biologics, and Janux Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Celldex Therapeutics financial statement analysis. It represents the amount of money remaining after all of Celldex Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Celldex Therapeutics | CLDX |
| Classification | Cancer Fighters |
| Business Address | Perryville III Building, |
| Exchange | NASDAQ Exchange |
USD 23.0
Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.